Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics Regains Rights for Tamoxifen Treatment Response Test from Roche

NEW YORK, Jan. 30 (GenomeWeb News) - Epigenomics said today that its has regained the full rights to a tamoxifen treatment response test from Roche Diagnostics.

 

Epigenomics, which is focused on developing tests based on DNA methylation, said that it will now handle the full development of the test itself.

 

The tissue-based test is designed to predict the probability of disease recurrence in breast cancer patients, and was part of a multi-product collaboration with Roche Diagnostics, Epigenomics said.

 

The companies are still collaborating on the development of three screening products for colon, prostate and breast cancers.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.